Niels Sharman

Senior Investment Manager

Niels Sharman

Senior Investment Manager

Niels Sharman has been supporting the life science investment team since November 2020. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and worked for two biotech start-ups.

Telefon:
+49 – (0) 228 – 82300 – 187

Portfolio

Posts & mentions

Press
15. May 2023

Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including "Nia," the most widely downloaded app for people with atopic dermatitis. The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics. The great potential lies above all in Nia Health's ex
 
Press
1. September 2022

C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring

C-mo Medical Solutions is an award-winning start-up that is unravelling the potential of assessing cough towards improved diagnosis, treatment courses and disease management. The company has now raised 4.1€Mn in a seed round led by Boehringer Ingelheim Venture Fund. This investment will allow the company to bring its innovative cough-monitoring technology to the market. Lisbon, 1 September 2022 – C-mo Medical Solutions has announced today the closing of a 4.1€Mn seed investment roun
 
Press
31. March 2022

Improving ARDS treatment with digital twins: Ebenbuild secures seed financing round led by Bayern Kapital and High-Tech Gründerfonds

Munich/Bonn/Landshut, 31 March 2022 - Software start-up Ebenbuild has secured seven-figure funding as part of a seed financing round. Alongside lead investors High-Tech Gründerfonds and Bayern Kapital, the venture and growth capital organisation of the state of Bavaria, a number of well-known business angels also invested in the Munich-based HealthTech start-up, with the funding amounting to €2.5 million. Ebenbuild develops personalised lung simulation models based on patient data. These
 
Press
altavo founders
27. January 2022

Altavo completes Seed Financing Round for the Development of AI-based Voice Prosthetics

Altavo GmbH, a speech technology and medical technology spin-off of TU Dresden, successfully completed its seed financing round in December 2021. A consortium led by High-Tech Gründerfonds (HTGF) is investing in the development of Altavo’s AI-based speech prosthesis. Altavo is developing a non-invasive prosthesis aimed at restoring an individual, natural-sounding voice for people who have lost their voice, for example, due to laryngectomy. The approach is based on non-invasive radar se
 
Press
LOEWI Founders
26. January 2022

UK-based health tech company bioniq acquires LOEWI

LOEWI is a scientific spin-off of the TU München, which provides tailor-made nutrients based on your blood work and lifestyleThe acquisition is a continuation of bioniq´s global expansion and accelerates the European market presenceHigh-Tech Gründerfonds invested in LOEWI´s seed round in 2020   London, January 26th – Through the acquisition to the UK-based health tech company bioniq, High-Tech Gründerfonds (HTGF) has sold its stake in LOEWI, a scientific spin-off of the TU